1. Home
  2. HROW vs BRAI Comparison

HROW vs BRAI Comparison

Compare HROW & BRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HROW

Harrow Inc.

HOLD

Current Price

$28.43

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Braiin Limited Common Stock

BRAI

Braiin Limited Common Stock

HOLD

Current Price

$3.73

Market Cap

929.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HROW
BRAI
Founded
1998
2022
Country
United States
Australia
Employees
N/A
800
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
929.5M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
HROW
BRAI
Price
$28.43
$3.73
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
★ $65.00
N/A
AVG Volume (30 Days)
★ 550.4K
35.7K
Earning Date
11-09-2026
11-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 71.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$28.59
N/A
Revenue Next Year
$53.17
$30.00
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.96
$3.93
52 Week High
$54.98
$32.32

Technical Indicators

Market Signals
Indicator
HROW
BRAI
Relative Strength Index (RSI) 36.73 28.45
Support Level $26.96 N/A
Resistance Level $35.87 $5.87
Average True Range (ATR) 1.41 0.49
MACD 0.19 -0.08
Stochastic Oscillator 36.39 9.92

Price Performance

Historical Comparison
HROW
BRAI

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

About BRAI Braiin Limited Common Stock

Braiin Ltd is an Australian technology company leveraging proprietary intellectual property and patented artificial intelligence/machine learning (AI/ML) technologies to deliver actionable insights across the verticals: Agriculture, Property Technology, and Customer Experience as a Service (CXaaS). The company's platforms are designed to address inefficiencies and drive data-backed decision-making across traditionally analog sectors. It prominently focuses on the agriculture technology sector, where it has successfully deployed its AI-powered solutions across multiple implementations. It provides end-to-end solutions to improve farming productivity using IoTs, Wireless Connectivity, Robotics, Software and AI/ML.

Share on Social Networks: